NewLink Genetics

^{, Nasdaq: NLNK}

Developing a Phase 3 drug for surgically-resected pancreatic cancer patients.

Industry: Health Care

First Day Return: +1.1%

NLNK

Developing a Phase 3 drug for surgically-resected pancreatic cancer patients.

IPO News for NewLink Genetics

NewLink Genetics prices IPO at $7, below the range 11/11/11
US IPO Calendar erupts, 16 deals set to price in November 11/08/11
5 IPOs planned for the week of Nov 7 11/07/11

IPO Data
IPO Date	11/10/2011
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$43
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.linkp.com
Headquarters	Ames, IA, United States
Founded	1999
Employees at IPO	78

IPO News for NewLink Genetics

NewLink Genetics prices IPO at $7, below the range 11/11/11
US IPO Calendar erupts, 16 deals set to price in November 11/08/11
5 IPOs planned for the week of Nov 7 11/07/11

NewLink Genetics (NLNK) Performance